FibroBiologics (FBLG) Notes Payables (2022 - 2025)

FibroBiologics (FBLG) has reported Notes Payables for 3 consecutive years, with $11.6 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Notes Payables rose 16.0% year-over-year to $11.6 million; the trailing twelve-month figure through Dec 2025 stood at $11.6 million (up 16.0% YoY), and the FY2025 full-year result was $11.6 million, up 16.0% from the prior year.
• Notes Payables improved to $11.6 million in Q4 2025 per FBLG's latest filing, from $9.7 million in the prior quarter.
• Across five years, Notes Payables topped out at $11.6 million in Q4 2025 and bottomed at $115000.0 in Q3 2024.
• Historically, Notes Payables has averaged $5.7 million across 3 years, with a median of $5.8 million in 2025.
• The widest YoY moves for Notes Payables: up 8334.78% in 2025, down 16.0% in 2025.
• Over 3 years, Notes Payables stood at $5.5 million in 2022, then jumped by 83.45% to $10.0 million in 2024, then climbed by 16.0% to $11.6 million in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $11.6 million, $9.7 million, and $8.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.